RecruitingT2DMDiabete Type 2DM
Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin
Eligible age
19+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.
Sponsor: Celltrion
You may qualify if…
- ✓ Adults at the time of signing the Informed Consent Form (ICF)
- ✓ Signed the written ICF voluntarily after being fully informed of the objectives, methods, and effects of the study
- ✓ Diagnosed with T2DM
You may not qualify if…
- ✕ Diagnosed with other types of diabetes than T2DM
- ✕ History of hypersensitivity reaction to the components or drugs of the same class as the IP or the background therapy
- ✕ Uncontrolled severe complications of diabetes
Source: ClinicalTrials.gov · NCT07093476 · last updated 2025-08-11